Skip Header

You are using a version of browser that may not display all the features of this website. Please consider upgrading your browser.
Protein

Peroxisome proliferator-activated receptor gamma

Gene

PPARG

Organism
Homo sapiens (Human)
Status
Reviewed-Annotation score: Annotation score: 5 out of 5-Experimental evidence at protein leveli

Functioni

Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. ARF6 acts as a key regulator of the tissue-specific adipocyte P2 (aP2) enhancer. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses. Plays a role in the regulation of cardiovascular circadian rhythms by regulating the transcription of ARNTL/BMAL1 in the blood vessels (By similarity).By similarity4 Publications

Enzyme regulationi

PDPK1 activates its transcriptional activity independently of its kinase activity.1 Publication

Sites

Feature keyPosition(s)LengthDescriptionGraphical viewFeature identifierActions
Binding sitei317 – 3171Synthetic agonist9 Publications
Binding sitei351 – 3511Synthetic agonist9 Publications
Binding sitei477 – 4771Synthetic agonist9 Publications
Binding sitei501 – 5011Synthetic agonist9 Publications

Regions

Feature keyPosition(s)LengthDescriptionGraphical viewFeature identifierActions
DNA bindingi136 – 21075Nuclear receptorPROSITE-ProRule annotationAdd
BLAST
Zinc fingeri139 – 15921NR C4-typePROSITE-ProRule annotationAdd
BLAST
Zinc fingeri176 – 19823NR C4-typePROSITE-ProRule annotationAdd
BLAST

GO - Molecular functioni

  • activating transcription factor binding Source: BHF-UCL
  • alpha-actinin binding Source: UniProtKB
  • arachidonic acid binding Source: BHF-UCL
  • chromatin binding Source: UniProtKB
  • core promoter sequence-specific DNA binding Source: UniProtKB
  • DNA binding Source: UniProtKB
  • drug binding Source: BHF-UCL
  • enzyme binding Source: UniProtKB
  • ligand-activated sequence-specific DNA binding RNA polymerase II transcription factor activity Source: BHF-UCL
  • ligand-dependent nuclear receptor transcription coactivator activity Source: UniProtKB
  • prostaglandin receptor activity Source: BHF-UCL
  • retinoid X receptor binding Source: BHF-UCL
  • RNA polymerase II regulatory region DNA binding Source: Ensembl
  • RNA polymerase II transcription regulatory region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription Source: Ensembl
  • sequence-specific DNA binding transcription factor activity Source: BHF-UCL
  • steroid hormone receptor activity Source: InterPro
  • transcription regulatory region DNA binding Source: BHF-UCL
  • zinc ion binding Source: InterPro

GO - Biological processi

  • activation of cysteine-type endopeptidase activity involved in apoptotic process Source: BHF-UCL
  • brown fat cell differentiation Source: Ensembl
  • cell fate commitment Source: BHF-UCL
  • cell maturation Source: BHF-UCL
  • cellular response to hyperoxia Source: Ensembl
  • cellular response to insulin stimulus Source: BHF-UCL
  • cellular response to lithium ion Source: Ensembl
  • cellular response to prostaglandin E stimulus Source: Ensembl
  • cellular response to retinoic acid Source: Ensembl
  • cellular response to vitamin E Source: Ensembl
  • diet induced thermogenesis Source: Ensembl
  • epithelial cell differentiation Source: BHF-UCL
  • fatty acid oxidation Source: Ensembl
  • gene expression Source: Reactome
  • glucose homeostasis Source: BHF-UCL
  • G-protein coupled receptor signaling pathway Source: GOC
  • heart development Source: Ensembl
  • innate immune response Source: BHF-UCL
  • lipid homeostasis Source: BHF-UCL
  • lipid metabolic process Source: ProtInc
  • lipoprotein transport Source: BHF-UCL
  • long-chain fatty acid transport Source: BHF-UCL
  • low-density lipoprotein particle receptor biosynthetic process Source: BHF-UCL
  • monocyte differentiation Source: BHF-UCL
  • negative regulation of acute inflammatory response Source: Ensembl
  • negative regulation of cell growth Source: Ensembl
  • negative regulation of cholesterol storage Source: BHF-UCL
  • negative regulation of collagen biosynthetic process Source: Ensembl
  • negative regulation of interferon-gamma-mediated signaling pathway Source: BHF-UCL
  • negative regulation of macrophage derived foam cell differentiation Source: BHF-UCL
  • negative regulation of pancreatic stellate cell proliferation Source: Ensembl
  • negative regulation of receptor biosynthetic process Source: BHF-UCL
  • negative regulation of sequestering of triglyceride Source: BHF-UCL
  • negative regulation of smooth muscle cell proliferation Source: BHF-UCL
  • negative regulation of telomerase activity Source: Ensembl
  • negative regulation of transcription, DNA-templated Source: BHF-UCL
  • negative regulation of transcription from RNA polymerase II promoter Source: BHF-UCL
  • organ regeneration Source: Ensembl
  • peroxisome proliferator activated receptor signaling pathway Source: BHF-UCL
  • placenta development Source: BHF-UCL
  • positive regulation of fat cell differentiation Source: HGNC
  • positive regulation of fatty acid oxidation Source: Ensembl
  • positive regulation of oligodendrocyte differentiation Source: Ensembl
  • positive regulation of phagocytosis, engulfment Source: Ensembl
  • positive regulation of sequence-specific DNA binding transcription factor activity Source: BHF-UCL
  • positive regulation of transcription, DNA-templated Source: BHF-UCL
  • positive regulation of transcription from RNA polymerase II promoter Source: UniProtKB
  • regulation of blood pressure Source: BHF-UCL
  • regulation of cholesterol transporter activity Source: BHF-UCL
  • regulation of circadian rhythm Source: UniProtKB
  • regulation of transcription involved in cell fate commitment Source: UniProtKB
  • response to caffeine Source: Ensembl
  • response to cold Source: Ensembl
  • response to diuretic Source: Ensembl
  • response to estrogen Source: Ensembl
  • response to immobilization stress Source: Ensembl
  • response to lipid Source: BHF-UCL
  • response to low-density lipoprotein particle Source: BHF-UCL
  • response to mechanical stimulus Source: Ensembl
  • response to metformin Source: Ensembl
  • response to nutrient Source: ProtInc
  • response to retinoic acid Source: UniProtKB
  • response to starvation Source: Ensembl
  • response to vitamin A Source: Ensembl
  • rhythmic process Source: UniProtKB-KW
  • signal transduction Source: BHF-UCL
  • transcription initiation from RNA polymerase II promoter Source: Reactome
  • white fat cell differentiation Source: UniProtKB
Complete GO annotation...

Keywords - Molecular functioni

Activator, Receptor

Keywords - Biological processi

Biological rhythms, Transcription, Transcription regulation

Keywords - Ligandi

DNA-binding, Metal-binding, Zinc

Enzyme and pathway databases

ReactomeiREACT_116145. PPARA activates gene expression.
REACT_15525. Nuclear Receptor transcription pathway.
REACT_27161. Transcriptional regulation of white adipocyte differentiation.
SignaLinkiP37231.

Names & Taxonomyi

Protein namesi
Recommended name:
Peroxisome proliferator-activated receptor gamma
Short name:
PPAR-gamma
Alternative name(s):
Nuclear receptor subfamily 1 group C member 3
Gene namesi
Name:PPARG
Synonyms:NR1C3
OrganismiHomo sapiens (Human)
Taxonomic identifieri9606 [NCBI]
Taxonomic lineageiEukaryotaMetazoaChordataCraniataVertebrataEuteleostomiMammaliaEutheriaEuarchontogliresPrimatesHaplorrhiniCatarrhiniHominidaeHomo
ProteomesiUP000005640 Componenti: Chromosome 3

Organism-specific databases

HGNCiHGNC:9236. PPARG.

Subcellular locationi

  • Nucleus
  • Cytoplasm

  • Note: Redistributed from the nucleus to the cytosol through a MAP2K1/MEK1-dependent manner. CCRN4L/NOC enhances its nuclear translocation.

GO - Cellular componenti

  • cytosol Source: BHF-UCL
  • nucleoplasm Source: Reactome
  • nucleus Source: BHF-UCL
  • perinuclear region of cytoplasm Source: Ensembl
  • RNA polymerase II transcription factor complex Source: BHF-UCL
Complete GO annotation...

Keywords - Cellular componenti

Cytoplasm, Nucleus

Pathology & Biotechi

Involvement in diseasei

Defects in PPARG can lead to type 2 insulin-resistant diabetes and hyptertension. PPARG mutations may be associated with colon cancer.

Obesity (OBESITY)1 Publication

Disease susceptibility may be associated with variations affecting the gene represented in this entry.

Disease descriptionA condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat.

See also OMIM:601665
Lipodystrophy, familial partial, 3 (FPLD3)2 Publications

The disease is caused by mutations affecting the gene represented in this entry.

Disease descriptionA form of lipodystrophy characterized by marked loss of subcutaneous fat from the extremities. Facial adipose tissue may be increased, decreased or normal. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia.

See also OMIM:604367
Feature keyPosition(s)LengthDescriptionGraphical viewFeature identifierActions
Natural varianti388 – 3881F → L in FPLD3. 1 Publication
VAR_022700
Natural varianti425 – 4251R → C in FPLD3. 1 Publication
VAR_022701
Glioma 1 (GLM1)

Disease susceptibility may be associated with variations affecting the gene represented in this entry. Polymorphic PPARG alleles have been found to be significantly over-represented among a cohort of American patients with sporadic glioblastoma multiforme suggesting a possible contribution to disease susceptibility.

Disease descriptionGliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes.

See also OMIM:137800

Keywords - Diseasei

Diabetes mellitus, Disease mutation, Obesity

Organism-specific databases

MIMi137800. phenotype.
601665. phenotype.
604367. phenotype.
606641. phenotype.
609338. phenotype.
Orphaneti528. Berardinelli-Seip congenital lipodystrophy.
79083. Familial partial lipodystrophy associated with PPARG mutations.
251579. Giant cell glioblastoma.
251576. Gliosarcoma.
PharmGKBiPA281.

Chemistry

DrugBankiDB01014. Balsalazide.
DB01393. Bezafibrate.
DB01067. Glipizide.
DB01050. Ibuprofen.
DB00159. Icosapent.
DB00328. Indomethacin.
DB00244. Mesalazine.
DB01252. Mitiglinide.
DB00731. Nateglinide.
DB01132. Pioglitazone.
DB00912. Repaglinide.
DB00412. Rosiglitazone.
DB00795. Sulfasalazine.
DB00966. Telmisartan.

Polymorphism and mutation databases

BioMutaiPPARG.
DMDMi13432234.

PTM / Processingi

Molecule processing

Feature keyPosition(s)LengthDescriptionGraphical viewFeature identifierActions
Chaini1 – 505505Peroxisome proliferator-activated receptor gammaPRO_0000053492Add
BLAST

Amino acid modifications

Feature keyPosition(s)LengthDescriptionGraphical viewFeature identifierActions
Glycosylationi84 – 841O-linked (GlcNAc)By similarity
Modified residuei112 – 1121Phosphoserine; by MAPKBy similarity

Post-translational modificationi

O-GlcNAcylation at Thr-84 reduces transcriptional activity in adipocytes.By similarity
Phosphorylated in basal conditions and dephosphorylated when treated with the ligand. May be dephosphorylated by PPP5C. The phosphorylated form may be inactive and dephosphorylation at Ser-112 induces adipogenic activity (By similarity).By similarity

Keywords - PTMi

Glycoprotein, Phosphoprotein

Proteomic databases

MaxQBiP37231.
PaxDbiP37231.
PRIDEiP37231.

PTM databases

PhosphoSiteiP37231.

Expressioni

Tissue specificityi

Highest expression in adipose tissue. Lower in skeletal muscle, spleen, heart and liver. Also detectable in placenta, lung and ovary.1 Publication

Gene expression databases

BgeeiP37231.
ExpressionAtlasiP37231. baseline and differential.
GenevisibleiP37231. HS.

Organism-specific databases

HPAiCAB004282.

Interactioni

Subunit structurei

Interacts with FOXO1 (acetylated form) (By similarity). Heterodimer with other nuclear receptors, such as RXRA. The heterodimer with the retinoic acid receptor RXRA is called adipocyte-specific transcription factor ARF6. Interacts with NCOA6 coactivator, leading to a strong increase in transcription of target genes. Interacts with coactivator PPARBP, leading to a mild increase in transcription of target genes. Interacts with NOCA7 in a ligand-inducible manner. Interacts with NCOA1 and NCOA2 LXXLL motifs. Interacts with ASXL1, ASXL2, DNTTIP2, FAM120B, MAP2K1/MEK1, NR0B2, PDPK1, PRDM16, PRMT2 and TGFB1I1. Interacts (when activated by agonist) with PPP5C. Interacts with HELZ2 and THRAP3; the interaction stimulates the transcriptional activity of PPARG. Interacts with PER2, the interaction is ligand dependent and blocks PPARG recruitment to target promoters. Interacts with CCRN4L/NOC. Interacts with ACTN4.By similarity21 Publications

Binary interactionsi

WithEntry#Exp.IntActNotes
CDK5Q005352EBI-781416,EBI-1041567
CLUP109093EBI-781384,EBI-1104674
EDF1O608694EBI-781384,EBI-781301
HTTP428584EBI-781384,EBI-466029
SMARCD3Q6STE5-13EBI-781384,EBI-488506
SMARCD3Q6STE5-23EBI-781384,EBI-488511

Protein-protein interaction databases

BioGridi111464. 133 interactions.
DIPiDIP-35528N.
IntActiP37231. 27 interactions.
STRINGi9606.ENSP00000287820.

Structurei

Secondary structure

1
505
Legend: HelixTurnBeta strand
Show more details
Feature keyPosition(s)LengthDescriptionGraphical viewFeature identifierActions
Beta strandi140 – 1423Combined sources
Beta strandi148 – 1503Combined sources
Beta strandi151 – 1544Combined sources
Helixi157 – 16711Combined sources
Turni168 – 1703Combined sources
Helixi186 – 1883Combined sources
Helixi191 – 20010Combined sources
Helixi205 – 2073Combined sources
Turni214 – 2174Combined sources
Helixi218 – 2203Combined sources
Turni222 – 2265Combined sources
Turni228 – 2314Combined sources
Helixi237 – 25317Combined sources
Helixi258 – 2658Combined sources
Turni266 – 2683Combined sources
Beta strandi269 – 2713Combined sources
Beta strandi275 – 2773Combined sources
Helixi280 – 2867Combined sources
Turni287 – 2893Combined sources
Beta strandi290 – 2923Combined sources
Beta strandi294 – 2963Combined sources
Beta strandi297 – 2993Combined sources
Beta strandi301 – 3033Combined sources
Helixi305 – 32925Combined sources
Helixi334 – 3363Combined sources
Helixi339 – 36022Combined sources
Beta strandi361 – 3633Combined sources
Beta strandi366 – 3694Combined sources
Turni370 – 3734Combined sources
Beta strandi374 – 3774Combined sources
Helixi378 – 3836Combined sources
Turni385 – 3873Combined sources
Helixi388 – 3903Combined sources
Helixi393 – 40311Combined sources
Helixi409 – 42012Combined sources
Beta strandi423 – 4253Combined sources
Helixi431 – 45222Combined sources
Beta strandi454 – 4563Combined sources
Helixi459 – 48628Combined sources
Beta strandi488 – 4903Combined sources
Helixi491 – 4933Combined sources
Helixi495 – 5017Combined sources

3D structure databases

Select the link destinations:
PDBei
RCSB PDBi
PDBji
Links Updated
EntryMethodResolution (Å)ChainPositionsPDBsum
1FM6X-ray2.10D/X234-505[»]
1FM9X-ray2.10D234-505[»]
1I7IX-ray2.35A/B225-505[»]
1K74X-ray2.30D234-505[»]
1KNUX-ray2.50A/B232-505[»]
1NYXX-ray2.65A/B230-505[»]
1PRGX-ray2.20A/B235-504[»]
1RDTX-ray2.40D235-505[»]
1WM0X-ray2.90X232-505[»]
1ZEOX-ray2.50A/B231-505[»]
1ZGYX-ray1.80A234-505[»]
2ATHX-ray2.28A/B235-505[»]
2F4BX-ray2.07A/B235-505[»]
2FVJX-ray1.99A235-505[»]
2G0GX-ray2.54A/B235-505[»]
2G0HX-ray2.30A/B235-505[»]
2GTKX-ray2.10A235-505[»]
2HFPX-ray2.00A234-505[»]
2HWQX-ray1.97A/B235-505[»]
2HWRX-ray2.34A/B235-505[»]
2I4JX-ray2.10A/B223-504[»]
2I4PX-ray2.10A/B223-504[»]
2I4ZX-ray2.25A/B223-504[»]
2OM9X-ray2.80A/B/C/D232-505[»]
2P4YX-ray2.25A/B231-505[»]
2POBX-ray2.30A/B234-505[»]
2PRGX-ray2.30A/B235-505[»]
2Q59X-ray2.20A/B233-505[»]
2Q5PX-ray2.30A/B233-505[»]
2Q5SX-ray2.05A/B233-505[»]
2Q61X-ray2.20A/B233-505[»]
2Q6RX-ray2.41A/B233-505[»]
2Q6SX-ray2.40A/B233-505[»]
2Q8SX-ray2.30A/B235-505[»]
2QMVNMR-A235-504[»]
2VSRX-ray2.05A/B232-505[»]
2VSTX-ray2.35A/B232-505[»]
2VV0X-ray2.55A/B232-505[»]
2VV1X-ray2.20A/B232-505[»]
2VV2X-ray2.75A/B232-505[»]
2VV3X-ray2.85A/B232-505[»]
2VV4X-ray2.35A/B232-505[»]
2XKWX-ray2.02A/B232-505[»]
2YFEX-ray2.00A/B223-505[»]
2ZK0X-ray2.36A/B223-504[»]
2ZK1X-ray2.61A/B223-504[»]
2ZK2X-ray2.26A/B223-504[»]
2ZK3X-ray2.58A/B223-504[»]
2ZK4X-ray2.57A/B223-504[»]
2ZK5X-ray2.45A/B223-504[»]
2ZK6X-ray2.41A/B223-504[»]
2ZNOX-ray2.40A/B223-504[»]
2ZVTX-ray1.90A/B223-504[»]
3ADSX-ray2.25A/B223-505[»]
3ADTX-ray2.70A/B223-505[»]
3ADUX-ray2.77A/B223-505[»]
3ADVX-ray2.27A/B223-505[»]
3ADWX-ray2.07A/B223-505[»]
3ADXX-ray1.95A/B223-505[»]
3AN3X-ray2.30A/B223-504[»]
3AN4X-ray2.30A/B223-504[»]
3B0QX-ray2.10A/B231-504[»]
3B0RX-ray2.15A/B231-504[»]
3B1MX-ray1.60A234-505[»]
3B3KX-ray2.60A/B223-504[»]
3BC5X-ray2.27A231-505[»]
3CDPX-ray2.80A/B223-504[»]
3CDSX-ray2.65A/B223-504[»]
3CS8X-ray2.30A234-504[»]
3CWDX-ray2.40A/B236-505[»]
3D6DX-ray2.40A/B223-504[»]
3DZUX-ray3.20D102-505[»]
3DZYX-ray3.10D102-505[»]
3E00X-ray3.10D102-505[»]
3ET0X-ray2.40A/B235-505[»]
3ET3X-ray1.95A235-505[»]
3FEJX-ray2.01A235-505[»]
3FURX-ray2.30A234-505[»]
3G9EX-ray2.30A235-505[»]
3GBKX-ray2.30A/B235-505[»]
3H0AX-ray2.10D234-505[»]
3HO0X-ray2.60A/B223-504[»]
3HODX-ray2.10A/B223-504[»]
3IA6X-ray2.31A/B235-505[»]
3K8SX-ray2.55A/B234-505[»]
3KMGX-ray2.10A/D234-505[»]
3LMPX-ray1.90A234-505[»]
3NOAX-ray1.98A/B235-505[»]
3OSIX-ray2.70A/B224-504[»]
3OSWX-ray2.55A/B224-504[»]
3PBAX-ray2.30A/B224-505[»]
3PO9X-ray2.35A/B224-505[»]
3PRGX-ray2.90A232-505[»]
3QT0X-ray2.50A235-505[»]
3R5NX-ray2.00A232-505[»]
3R8AX-ray2.41A/B235-505[»]
3R8IX-ray2.30A/B223-505[»]
3S9SX-ray2.55A234-505[»]
3SZ1X-ray2.30A/B232-505[»]
3T03X-ray2.10A/B234-505[»]
3TY0X-ray2.00A/B231-505[»]
3U9QX-ray1.52A236-504[»]
3V9TX-ray1.65A234-505[»]
3V9VX-ray1.60A234-505[»]
3V9YX-ray2.10A234-505[»]
3VJHX-ray2.22A/B223-504[»]
3VJIX-ray2.61A/B223-504[»]
3VN2X-ray2.18A225-505[»]
3VSOX-ray2.00A/B223-504[»]
3VSPX-ray2.40A/B223-504[»]
3WJ4X-ray1.95A/B235-505[»]
3WJ5X-ray1.89A/B235-505[»]
3WMHX-ray2.10A/B223-504[»]
3X1HX-ray2.30A/B232-505[»]
3X1IX-ray2.40A/B232-505[»]
4A4VX-ray2.00A/B223-505[»]
4A4WX-ray2.00A/B223-505[»]
4CI5X-ray1.77A/B234-505[»]
4E4KX-ray2.50A/B223-505[»]
4E4QX-ray2.50A/B223-505[»]
4EM9X-ray2.10A/B235-505[»]
4EMAX-ray2.54A/B235-505[»]
4F9MX-ray1.90A234-505[»]
4FGYX-ray2.84A235-504[»]
4HEEX-ray2.50X235-505[»]
4JAZX-ray2.85A/B223-505[»]
4JL4X-ray2.50A/B223-505[»]
4L96X-ray2.38A235-505[»]
4L98X-ray2.28A/B235-505[»]
4O8FX-ray2.60A/B223-505[»]
4OJ4X-ray2.30A232-505[»]
4PRGX-ray2.90A/B/C/D235-504[»]
4PVUX-ray2.60A/B223-505[»]
4PWLX-ray2.60A/B223-505[»]
DisProtiDP00718.
ProteinModelPortaliP37231.
SMRiP37231. Positions 135-505.
ModBaseiSearch...
MobiDBiSearch...

Miscellaneous databases

EvolutionaryTraceiP37231.

Family & Domainsi

Region

Feature keyPosition(s)LengthDescriptionGraphical viewFeature identifierActions
Regioni205 – 28076Interaction with FAM120BBy similarityAdd
BLAST
Regioni317 – 505189Ligand-bindingAdd
BLAST

Sequence similaritiesi

Contains 1 nuclear receptor DNA-binding domain.PROSITE-ProRule annotation

Zinc finger

Feature keyPosition(s)LengthDescriptionGraphical viewFeature identifierActions
Zinc fingeri139 – 15921NR C4-typePROSITE-ProRule annotationAdd
BLAST
Zinc fingeri176 – 19823NR C4-typePROSITE-ProRule annotationAdd
BLAST

Keywords - Domaini

Zinc-finger

Phylogenomic databases

eggNOGiNOG266867.
GeneTreeiENSGT00780000121834.
HOGENOMiHOG000119407.
HOVERGENiHBG106004.
InParanoidiP37231.
KOiK08530.
OMAiSTPHYED.
PhylomeDBiP37231.
TreeFamiTF316304.

Family and domain databases

Gene3Di1.10.565.10. 2 hits.
3.30.50.10. 1 hit.
InterProiIPR003074. 1Cnucl_rcpt.
IPR003077. 1Cnucl_rcpt_G.
IPR008946. Nucl_hormone_rcpt_ligand-bd.
IPR000536. Nucl_hrmn_rcpt_lig-bd_core.
IPR022590. PPARgamma_N.
IPR001723. Str_hrmn_rcpt.
IPR001628. Znf_hrmn_rcpt.
IPR013088. Znf_NHR/GATA.
[Graphical view]
PfamiPF00104. Hormone_recep. 1 hit.
PF12577. PPARgamma_N. 1 hit.
PF00105. zf-C4. 1 hit.
[Graphical view]
PRINTSiPR01288. PROXISOMEPAR.
PR01291. PROXISOMPAGR.
PR00398. STRDHORMONER.
PR00047. STROIDFINGER.
SMARTiSM00430. HOLI. 1 hit.
SM00399. ZnF_C4. 1 hit.
[Graphical view]
SUPFAMiSSF48508. SSF48508. 1 hit.
PROSITEiPS00031. NUCLEAR_REC_DBD_1. 1 hit.
PS51030. NUCLEAR_REC_DBD_2. 1 hit.
[Graphical view]

Sequences (3)i

Sequence statusi: Complete.

This entry describes 3 isoformsi produced by alternative splicing. AlignAdd to basket

Note: Additional isoforms seem to exist.

Isoform 2 (identifier: P37231-1) [UniParc]FASTAAdd to basket

This isoform has been chosen as the 'canonical' sequence. All positional information in this entry refers to it. This is also the sequence that appears in the downloadable versions of the entry.

« Hide

        10         20         30         40         50
MGETLGDSPI DPESDSFTDT LSANISQEMT MVDTEMPFWP TNFGISSVDL
60 70 80 90 100
SVMEDHSHSF DIKPFTTVDF SSISTPHYED IPFTRTDPVV ADYKYDLKLQ
110 120 130 140 150
EYQSAIKVEP ASPPYYSEKT QLYNKPHEEP SNSLMAIECR VCGDKASGFH
160 170 180 190 200
YGVHACEGCK GFFRRTIRLK LIYDRCDLNC RIHKKSRNKC QYCRFQKCLA
210 220 230 240 250
VGMSHNAIRF GRMPQAEKEK LLAEISSDID QLNPESADLR ALAKHLYDSY
260 270 280 290 300
IKSFPLTKAK ARAILTGKTT DKSPFVIYDM NSLMMGEDKI KFKHITPLQE
310 320 330 340 350
QSKEVAIRIF QGCQFRSVEA VQEITEYAKS IPGFVNLDLN DQVTLLKYGV
360 370 380 390 400
HEIIYTMLAS LMNKDGVLIS EGQGFMTREF LKSLRKPFGD FMEPKFEFAV
410 420 430 440 450
KFNALELDDS DLAIFIAVII LSGDRPGLLN VKPIEDIQDN LLQALELQLK
460 470 480 490 500
LNHPESSQLF AKLLQKMTDL RQIVTEHVQL LQVIKKTETD MSLHPLLQEI

YKDLY
Length:505
Mass (Da):57,620
Last modified:April 27, 2001 - v3
Checksum:i3933EFF36A0E4CAF
GO
Isoform 1 (identifier: P37231-2) [UniParc]FASTAAdd to basket

Also known as: PPARgamma1(wt)

The sequence of this isoform differs from the canonical sequence as follows:
     1-28: Missing.

Show »
Length:477
Mass (Da):54,681
Checksum:i1061C2074B739E0A
GO
Isoform 3 (identifier: P37231-3) [UniParc]FASTAAdd to basket

Also known as: PPARgamma1(tr)

The sequence of this isoform differs from the canonical sequence as follows:
     1-28: Missing.
     207-213: AIRFGRM → EELQKDS
     214-504: Missing.

Note: Exhibits dominant negative activity over isoform 1.
Show »
Length:186
Mass (Da):21,580
Checksum:i10E780305F860A5D
GO

Sequence cautioni

The sequence AAN38992.2 differs from that shown. Reason: Erroneous initiation. Translation N-terminally extended.Curated
The sequence BAA23354.1 differs from that shown. Reason: Erroneous gene model prediction. Curated
The sequence BAF83270.1 differs from that shown. Reason: Erroneous initiation. Translation N-terminally extended.Curated
The sequence CAA62153.1 differs from that shown. Reason: Erroneous initiation. Translation N-terminally extended.Curated

Experimental Info

Feature keyPosition(s)LengthDescriptionGraphical viewFeature identifierActions
Sequence conflicti36 – 372MP → IA in BAA18949 (PubMed:9144532).Curated
Sequence conflicti213 – 2142MP → IA in BAA18949 (PubMed:9144532).Curated
Sequence conflicti240 – 2401R → RQ in BAA18949 (PubMed:9144532).Curated

Polymorphismi

Genetic variation in PPARG may influence body mass index (BMI) [MIMi:606641]. BMI reflects the amount of fat, lean mass, and body build.
Genetic variations in PPARG influence the carotid intimal medial thickness (CIMT) [MIMi:609338]. CIMT is a measure of atherosclerosis that is independently associated with traditional atherosclerotic cardiovascular disease risk factors and coronary atherosclerotic burden. 35 to 45% of the variability in multivariable-adjusted CIMT is explained by genetic factors.

Natural variant

Feature keyPosition(s)LengthDescriptionGraphical viewFeature identifierActions
Natural varianti12 – 121P → A Significant independent determinant of CIMT; may protect from early atherosclerosis in subject at risk for diabetes; associated with BMI. 5 Publications
Corresponds to variant rs1801282 [ dbSNP | Ensembl ].
VAR_010723
Natural varianti40 – 401P → A.
Corresponds to variant rs1805192 [ dbSNP | Ensembl ].
VAR_016116
Natural varianti113 – 1131P → Q in obesity. 1 Publication
Corresponds to variant rs1800571 [ dbSNP | Ensembl ].
VAR_010724
Natural varianti314 – 3141Q → P in colon cancer; sporadic; somatic mutation; loss of ligand-binding. 1 Publication
Corresponds to variant rs28936407 [ dbSNP | Ensembl ].
VAR_010725
Natural varianti316 – 3161R → H in colon cancer; sporadic; somatic mutation; partial loss of ligand-binding. 1 Publication
Corresponds to variant rs28936407 [ dbSNP | Ensembl ].
VAR_010726
Natural varianti318 – 3181V → M in diabetes. 1 Publication
VAR_010727
Natural varianti388 – 3881F → L in FPLD3. 1 Publication
VAR_022700
Natural varianti425 – 4251R → C in FPLD3. 1 Publication
VAR_022701
Natural varianti495 – 4951P → L in diabetes. 1 Publication
VAR_010728

Alternative sequence

Feature keyPosition(s)LengthDescriptionGraphical viewFeature identifierActions
Alternative sequencei1 – 2828Missing in isoform 1 and isoform 3. 7 PublicationsVSP_003645Add
BLAST
Alternative sequencei207 – 2137AIRFGRM → EELQKDS in isoform 3. 1 PublicationVSP_043906
Alternative sequencei214 – 504291Missing in isoform 3. 1 PublicationVSP_043907Add
BLAST

Sequence databases

Select the link destinations:
EMBLi
GenBanki
DDBJi
Links Updated
U79012 mRNA. Translation: AAC51248.1.
U63415 mRNA. Translation: AAB04028.1.
D83233 mRNA. Translation: BAA18949.1.
L40904 mRNA. Translation: AAA80314.2.
AB005526 Genomic DNA. Translation: BAA23354.1. Sequence problems.
X90563 mRNA. Translation: CAA62152.1.
X90563 mRNA. Translation: CAA62153.1. Different initiation.
DQ356894 mRNA. Translation: ABC97372.1.
BT007281 mRNA. Translation: AAP35945.1.
AK290581 mRNA. Translation: BAF83270.1. Different initiation.
AB451337 mRNA. Translation: BAG70151.1.
AB451486 mRNA. Translation: BAG70300.1.
AY157024 Genomic DNA. Translation: AAN38992.2. Different initiation.
AC090947 Genomic DNA. No translation available.
AC091492 Genomic DNA. No translation available.
AC093174 Genomic DNA. No translation available.
CH471055 Genomic DNA. Translation: EAW64124.1.
BC006811 mRNA. Translation: AAH06811.1.
CCDSiCCDS2609.1. [P37231-1]
CCDS2610.2. [P37231-2]
PIRiJC4859.
PC4290.
PC4429.
RefSeqiNP_005028.4. NM_005037.5. [P37231-2]
NP_056953.2. NM_015869.4. [P37231-1]
NP_619725.2. NM_138711.3. [P37231-2]
NP_619726.2. NM_138712.3. [P37231-2]
XP_011532142.1. XM_011533840.1. [P37231-2]
XP_011532143.1. XM_011533841.1. [P37231-2]
UniGeneiHs.162646.

Genome annotation databases

EnsembliENST00000287820; ENSP00000287820; ENSG00000132170.
ENST00000396999; ENSP00000380195; ENSG00000132170. [P37231-3]
GeneIDi5468.
KEGGihsa:5468.
UCSCiuc003bwr.3. human. [P37231-1]

Keywords - Coding sequence diversityi

Alternative splicing, Polymorphism

Cross-referencesi

Web resourcesi

Atlas of Genetics and Cytogenetics in Oncology and Haematology
Wikipedia

Peroxisome proliferator-activated receptor entry

SeattleSNPs
SHMPD

The Singapore human mutation and polymorphism database

Sequence databases

Select the link destinations:
EMBLi
GenBanki
DDBJi
Links Updated
U79012 mRNA. Translation: AAC51248.1.
U63415 mRNA. Translation: AAB04028.1.
D83233 mRNA. Translation: BAA18949.1.
L40904 mRNA. Translation: AAA80314.2.
AB005526 Genomic DNA. Translation: BAA23354.1. Sequence problems.
X90563 mRNA. Translation: CAA62152.1.
X90563 mRNA. Translation: CAA62153.1. Different initiation.
DQ356894 mRNA. Translation: ABC97372.1.
BT007281 mRNA. Translation: AAP35945.1.
AK290581 mRNA. Translation: BAF83270.1. Different initiation.
AB451337 mRNA. Translation: BAG70151.1.
AB451486 mRNA. Translation: BAG70300.1.
AY157024 Genomic DNA. Translation: AAN38992.2. Different initiation.
AC090947 Genomic DNA. No translation available.
AC091492 Genomic DNA. No translation available.
AC093174 Genomic DNA. No translation available.
CH471055 Genomic DNA. Translation: EAW64124.1.
BC006811 mRNA. Translation: AAH06811.1.
CCDSiCCDS2609.1. [P37231-1]
CCDS2610.2. [P37231-2]
PIRiJC4859.
PC4290.
PC4429.
RefSeqiNP_005028.4. NM_005037.5. [P37231-2]
NP_056953.2. NM_015869.4. [P37231-1]
NP_619725.2. NM_138711.3. [P37231-2]
NP_619726.2. NM_138712.3. [P37231-2]
XP_011532142.1. XM_011533840.1. [P37231-2]
XP_011532143.1. XM_011533841.1. [P37231-2]
UniGeneiHs.162646.

3D structure databases

Select the link destinations:
PDBei
RCSB PDBi
PDBji
Links Updated
EntryMethodResolution (Å)ChainPositionsPDBsum
1FM6X-ray2.10D/X234-505[»]
1FM9X-ray2.10D234-505[»]
1I7IX-ray2.35A/B225-505[»]
1K74X-ray2.30D234-505[»]
1KNUX-ray2.50A/B232-505[»]
1NYXX-ray2.65A/B230-505[»]
1PRGX-ray2.20A/B235-504[»]
1RDTX-ray2.40D235-505[»]
1WM0X-ray2.90X232-505[»]
1ZEOX-ray2.50A/B231-505[»]
1ZGYX-ray1.80A234-505[»]
2ATHX-ray2.28A/B235-505[»]
2F4BX-ray2.07A/B235-505[»]
2FVJX-ray1.99A235-505[»]
2G0GX-ray2.54A/B235-505[»]
2G0HX-ray2.30A/B235-505[»]
2GTKX-ray2.10A235-505[»]
2HFPX-ray2.00A234-505[»]
2HWQX-ray1.97A/B235-505[»]
2HWRX-ray2.34A/B235-505[»]
2I4JX-ray2.10A/B223-504[»]
2I4PX-ray2.10A/B223-504[»]
2I4ZX-ray2.25A/B223-504[»]
2OM9X-ray2.80A/B/C/D232-505[»]
2P4YX-ray2.25A/B231-505[»]
2POBX-ray2.30A/B234-505[»]
2PRGX-ray2.30A/B235-505[»]
2Q59X-ray2.20A/B233-505[»]
2Q5PX-ray2.30A/B233-505[»]
2Q5SX-ray2.05A/B233-505[»]
2Q61X-ray2.20A/B233-505[»]
2Q6RX-ray2.41A/B233-505[»]
2Q6SX-ray2.40A/B233-505[»]
2Q8SX-ray2.30A/B235-505[»]
2QMVNMR-A235-504[»]
2VSRX-ray2.05A/B232-505[»]
2VSTX-ray2.35A/B232-505[»]
2VV0X-ray2.55A/B232-505[»]
2VV1X-ray2.20A/B232-505[»]
2VV2X-ray2.75A/B232-505[»]
2VV3X-ray2.85A/B232-505[»]
2VV4X-ray2.35A/B232-505[»]
2XKWX-ray2.02A/B232-505[»]
2YFEX-ray2.00A/B223-505[»]
2ZK0X-ray2.36A/B223-504[»]
2ZK1X-ray2.61A/B223-504[»]
2ZK2X-ray2.26A/B223-504[»]
2ZK3X-ray2.58A/B223-504[»]
2ZK4X-ray2.57A/B223-504[»]
2ZK5X-ray2.45A/B223-504[»]
2ZK6X-ray2.41A/B223-504[»]
2ZNOX-ray2.40A/B223-504[»]
2ZVTX-ray1.90A/B223-504[»]
3ADSX-ray2.25A/B223-505[»]
3ADTX-ray2.70A/B223-505[»]
3ADUX-ray2.77A/B223-505[»]
3ADVX-ray2.27A/B223-505[»]
3ADWX-ray2.07A/B223-505[»]
3ADXX-ray1.95A/B223-505[»]
3AN3X-ray2.30A/B223-504[»]
3AN4X-ray2.30A/B223-504[»]
3B0QX-ray2.10A/B231-504[»]
3B0RX-ray2.15A/B231-504[»]
3B1MX-ray1.60A234-505[»]
3B3KX-ray2.60A/B223-504[»]
3BC5X-ray2.27A231-505[»]
3CDPX-ray2.80A/B223-504[»]
3CDSX-ray2.65A/B223-504[»]
3CS8X-ray2.30A234-504[»]
3CWDX-ray2.40A/B236-505[»]
3D6DX-ray2.40A/B223-504[»]
3DZUX-ray3.20D102-505[»]
3DZYX-ray3.10D102-505[»]
3E00X-ray3.10D102-505[»]
3ET0X-ray2.40A/B235-505[»]
3ET3X-ray1.95A235-505[»]
3FEJX-ray2.01A235-505[»]
3FURX-ray2.30A234-505[»]
3G9EX-ray2.30A235-505[»]
3GBKX-ray2.30A/B235-505[»]
3H0AX-ray2.10D234-505[»]
3HO0X-ray2.60A/B223-504[»]
3HODX-ray2.10A/B223-504[»]
3IA6X-ray2.31A/B235-505[»]
3K8SX-ray2.55A/B234-505[»]
3KMGX-ray2.10A/D234-505[»]
3LMPX-ray1.90A234-505[»]
3NOAX-ray1.98A/B235-505[»]
3OSIX-ray2.70A/B224-504[»]
3OSWX-ray2.55A/B224-504[»]
3PBAX-ray2.30A/B224-505[»]
3PO9X-ray2.35A/B224-505[»]
3PRGX-ray2.90A232-505[»]
3QT0X-ray2.50A235-505[»]
3R5NX-ray2.00A232-505[»]
3R8AX-ray2.41A/B235-505[»]
3R8IX-ray2.30A/B223-505[»]
3S9SX-ray2.55A234-505[»]
3SZ1X-ray2.30A/B232-505[»]
3T03X-ray2.10A/B234-505[»]
3TY0X-ray2.00A/B231-505[»]
3U9QX-ray1.52A236-504[»]
3V9TX-ray1.65A234-505[»]
3V9VX-ray1.60A234-505[»]
3V9YX-ray2.10A234-505[»]
3VJHX-ray2.22A/B223-504[»]
3VJIX-ray2.61A/B223-504[»]
3VN2X-ray2.18A225-505[»]
3VSOX-ray2.00A/B223-504[»]
3VSPX-ray2.40A/B223-504[»]
3WJ4X-ray1.95A/B235-505[»]
3WJ5X-ray1.89A/B235-505[»]
3WMHX-ray2.10A/B223-504[»]
3X1HX-ray2.30A/B232-505[»]
3X1IX-ray2.40A/B232-505[»]
4A4VX-ray2.00A/B223-505[»]
4A4WX-ray2.00A/B223-505[»]
4CI5X-ray1.77A/B234-505[»]
4E4KX-ray2.50A/B223-505[»]
4E4QX-ray2.50A/B223-505[»]
4EM9X-ray2.10A/B235-505[»]
4EMAX-ray2.54A/B235-505[»]
4F9MX-ray1.90A234-505[»]
4FGYX-ray2.84A235-504[»]
4HEEX-ray2.50X235-505[»]
4JAZX-ray2.85A/B223-505[»]
4JL4X-ray2.50A/B223-505[»]
4L96X-ray2.38A235-505[»]
4L98X-ray2.28A/B235-505[»]
4O8FX-ray2.60A/B223-505[»]
4OJ4X-ray2.30A232-505[»]
4PRGX-ray2.90A/B/C/D235-504[»]
4PVUX-ray2.60A/B223-505[»]
4PWLX-ray2.60A/B223-505[»]
DisProtiDP00718.
ProteinModelPortaliP37231.
SMRiP37231. Positions 135-505.
ModBaseiSearch...
MobiDBiSearch...

Protein-protein interaction databases

BioGridi111464. 133 interactions.
DIPiDIP-35528N.
IntActiP37231. 27 interactions.
STRINGi9606.ENSP00000287820.

Chemistry

BindingDBiP37231.
ChEMBLiCHEMBL2095162.
DrugBankiDB01014. Balsalazide.
DB01393. Bezafibrate.
DB01067. Glipizide.
DB01050. Ibuprofen.
DB00159. Icosapent.
DB00328. Indomethacin.
DB00244. Mesalazine.
DB01252. Mitiglinide.
DB00731. Nateglinide.
DB01132. Pioglitazone.
DB00912. Repaglinide.
DB00412. Rosiglitazone.
DB00795. Sulfasalazine.
DB00966. Telmisartan.
GuidetoPHARMACOLOGYi595.

PTM databases

PhosphoSiteiP37231.

Polymorphism and mutation databases

BioMutaiPPARG.
DMDMi13432234.

Proteomic databases

MaxQBiP37231.
PaxDbiP37231.
PRIDEiP37231.

Protocols and materials databases

DNASUi5468.
Structural Biology KnowledgebaseSearch...

Genome annotation databases

EnsembliENST00000287820; ENSP00000287820; ENSG00000132170.
ENST00000396999; ENSP00000380195; ENSG00000132170. [P37231-3]
GeneIDi5468.
KEGGihsa:5468.
UCSCiuc003bwr.3. human. [P37231-1]

Organism-specific databases

CTDi5468.
GeneCardsiGC03P012328.
HGNCiHGNC:9236. PPARG.
HPAiCAB004282.
MIMi137800. phenotype.
601487. gene.
601665. phenotype.
604367. phenotype.
606641. phenotype.
609338. phenotype.
neXtProtiNX_P37231.
Orphaneti528. Berardinelli-Seip congenital lipodystrophy.
79083. Familial partial lipodystrophy associated with PPARG mutations.
251579. Giant cell glioblastoma.
251576. Gliosarcoma.
PharmGKBiPA281.
GenAtlasiSearch...

Phylogenomic databases

eggNOGiNOG266867.
GeneTreeiENSGT00780000121834.
HOGENOMiHOG000119407.
HOVERGENiHBG106004.
InParanoidiP37231.
KOiK08530.
OMAiSTPHYED.
PhylomeDBiP37231.
TreeFamiTF316304.

Enzyme and pathway databases

ReactomeiREACT_116145. PPARA activates gene expression.
REACT_15525. Nuclear Receptor transcription pathway.
REACT_27161. Transcriptional regulation of white adipocyte differentiation.
SignaLinkiP37231.

Miscellaneous databases

ChiTaRSiPPARG. human.
EvolutionaryTraceiP37231.
GeneWikiiPeroxisome_proliferator-activated_receptor_gamma.
GenomeRNAii5468.
NextBioi21164.
PROiP37231.
SOURCEiSearch...

Gene expression databases

BgeeiP37231.
ExpressionAtlasiP37231. baseline and differential.
GenevisibleiP37231. HS.

Family and domain databases

Gene3Di1.10.565.10. 2 hits.
3.30.50.10. 1 hit.
InterProiIPR003074. 1Cnucl_rcpt.
IPR003077. 1Cnucl_rcpt_G.
IPR008946. Nucl_hormone_rcpt_ligand-bd.
IPR000536. Nucl_hrmn_rcpt_lig-bd_core.
IPR022590. PPARgamma_N.
IPR001723. Str_hrmn_rcpt.
IPR001628. Znf_hrmn_rcpt.
IPR013088. Znf_NHR/GATA.
[Graphical view]
PfamiPF00104. Hormone_recep. 1 hit.
PF12577. PPARgamma_N. 1 hit.
PF00105. zf-C4. 1 hit.
[Graphical view]
PRINTSiPR01288. PROXISOMEPAR.
PR01291. PROXISOMPAGR.
PR00398. STRDHORMONER.
PR00047. STROIDFINGER.
SMARTiSM00430. HOLI. 1 hit.
SM00399. ZnF_C4. 1 hit.
[Graphical view]
SUPFAMiSSF48508. SSF48508. 1 hit.
PROSITEiPS00031. NUCLEAR_REC_DBD_1. 1 hit.
PS51030. NUCLEAR_REC_DBD_2. 1 hit.
[Graphical view]
ProtoNetiSearch...

Publicationsi

« Hide 'large scale' publications
  1. "Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists."
    Mukherjee R., Jow L., Croston G.E., Paterniti J.R. Jr.
    J. Biol. Chem. 272:8071-8076(1997) [PubMed] [Europe PMC] [Abstract]
    Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, TISSUE SPECIFICITY.
    Tissue: Heart.
  2. "Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2."
    Elbrecht A., Chen Y., Cullinan C.A., Hayes N., Leibowitz M.D., Moller D.E., Berger J.
    Biochem. Biophys. Res. Commun. 224:431-437(1996) [PubMed] [Europe PMC] [Abstract]
    Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
    Tissue: Adipose tissue.
  3. "Differential expression of PPAR gamma1 and gamma2 isoforms in human adipose tissue."
    Yanase T., Yashiro T., Takitani K., Kato S., Taniguchi S., Takayanagi R., Nawata H.
    Biochem. Biophys. Res. Commun. 233:320-324(1997) [PubMed] [Europe PMC] [Abstract]
    Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
    Tissue: Adipose tissue.
  4. "Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping."
    Greene M.E., Blumberg B., McBride O.W., Yi H.F., Kronquist K., Kwan K., Hsieh L., Greene G., Nimer S.D.
    Gene Expr. 4:281-299(1995) [PubMed] [Europe PMC] [Abstract]
    Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
    Tissue: Bone marrow.
  5. Greene M.E.
    Submitted (DEC-2001) to the EMBL/GenBank/DDBJ databases
    Cited for: SEQUENCE REVISION TO 36; 37; 213; 214 AND 240.
  6. "No coding mutations are detected in the peroxisome proliferator-activated receptor-gamma gene in Japanese patients with lipoatrophic diabetes."
    Okazawa H., Mori H., Tamori Y., Araki S., Niki T., Masugi J., Kawanishi M., Kubota T., Shinoda H., Kasuga M.
    Diabetes 46:1904-1906(1997) [PubMed] [Europe PMC] [Abstract]
    Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
    Tissue: Placenta.
  7. "A human peroxisome-proliferator-activated receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs."
    Lambe K.G., Tugwood J.D.
    Eur. J. Biochem. 239:1-7(1996) [PubMed] [Europe PMC] [Abstract]
    Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
    Tissue: Placenta.
  8. "Identification of a truncated alternative splicing variant of human PPARgamma1 that exhibits dominant negative activity."
    Kim H.J., Woo I.S., Kang E.S., Eun S.Y., Kim H.J., Lee J.H., Chang K.C., Kim J.H., Seo H.G.
    Biochem. Biophys. Res. Commun. 347:698-706(2006) [PubMed] [Europe PMC] [Abstract]
    Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
  9. "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."
    Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., Phelan M., Farmer A.
    Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases
    Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
  10. "Complete sequencing and characterization of 21,243 full-length human cDNAs."
    Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.
    , Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.
    Nat. Genet. 36:40-45(2004) [PubMed] [Europe PMC] [Abstract]
    Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
  11. "Human Protein Factory: an infrastructure to convert the human transcriptome into the in vitro-expressed human proteome of versatile utility."
    Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R., Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y., Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B.
    , Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y., Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A., Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y., Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T., Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y., Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S., Nomura N.
    Submitted (JUL-2008) to the EMBL/GenBank/DDBJ databases
    Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
  12. SeattleSNPs variation discovery resource
    Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases
    Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANT ALA-12.
  13. "The DNA sequence, annotation and analysis of human chromosome 3."
    Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J.
    , Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B., Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H., Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J., Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.
    Nature 440:1194-1198(2006) [PubMed] [Europe PMC] [Abstract]
    Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
  14. Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
  15. "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."
    The MGC Project Team
    Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract]
    Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
    Tissue: Placenta.
  16. "Cloning and characterization of RAP250, a nuclear receptor coactivator."
    Caira F., Antonson P., Pelto-Huikko M., Treuter E., Gustafsson J.-A.
    J. Biol. Chem. 275:5308-5317(2000) [PubMed] [Europe PMC] [Abstract]
    Cited for: INTERACTION WITH NCOA6.
  17. "Over-representation of PPARgamma sequence variants in sporadic cases of glioblastoma multiforme: preliminary evidence for common low penetrance modifiers for brain tumour risk in the general population."
    Zhou X.P., Smith W.M., Gimm O., Mueller E., Gao X., Sarraf P., Prior T.W., Plass C., von Deimling A., Black P.M., Yates A.J., Eng C.
    J. Med. Genet. 37:410-414(2000) [PubMed] [Europe PMC] [Abstract]
    Cited for: POSSIBLE INVOLVEMENT IN SUSCEPTIBILITY TO GLIOMA.
  18. "Identification of protein arginine methyltransferase 2 as a coactivator for estrogen receptor alpha."
    Qi C., Chang J., Zhu Y., Yeldandi A.V., Rao S.M., Zhu Y.-J.
    J. Biol. Chem. 277:28624-28630(2002) [PubMed] [Europe PMC] [Abstract]
    Cited for: INTERACTION WITH PRMT2.
  19. "ERAP140, a conserved tissue-specific nuclear receptor coactivator."
    Shao W., Halachmi S., Brown M.
    Mol. Cell. Biol. 22:3358-3372(2002) [PubMed] [Europe PMC] [Abstract]
    Cited for: INTERACTION WITH NOCA7.
  20. "ERBP, a novel estrogen receptor binding protein enhancing the activity of estrogen receptor."
    Bu H., Kashireddy P., Chang J., Zhu Y.T., Zhang Z., Zheng W., Rao S.M., Zhu Y.-J.
    Biochem. Biophys. Res. Commun. 317:54-59(2004) [PubMed] [Europe PMC] [Abstract]
    Cited for: INTERACTION WITH DNTTIP2.
  21. Cited for: INTERACTION WITH TGFB1I1.
  22. "Isolation and characterization of a transcriptional cofactor and its novel isoform that bind the DNA-binding domain of peroxisome proliferator-activated receptor gamma."
    Tomaru T., Satoh T., Yoshino S., Ishizuka T., Hashimoto K., Monden T., Yamada M., Mori M.
    Endocrinology 147:377-388(2006) [PubMed] [Europe PMC] [Abstract]
    Cited for: INTERACTION WITH HELZ2.
  23. "3-phosphoinositide-dependent protein kinase-1 activates the peroxisome proliferator-activated receptor-gamma and promotes adipocyte differentiation."
    Yin Y., Yuan H., Wang C., Pattabiraman N., Rao M., Pestell R.G., Glazer R.I.
    Mol. Endocrinol. 20:268-278(2006) [PubMed] [Europe PMC] [Abstract]
    Cited for: FUNCTION, INTERACTION WITH PDPK1, ENZYME REGULATION.
  24. "Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor gamma."
    Burgermeister E., Chuderland D., Hanoch T., Meyer M., Liscovitch M., Seger R.
    Mol. Cell. Biol. 27:803-817(2007) [PubMed] [Europe PMC] [Abstract]
    Cited for: INTERACTION WITH MAP2K1/MEK1, SUBCELLULAR LOCATION.
  25. "Endoplasmic reticulum stress-activated C/EBP homologous protein enhances nuclear factor-kappaB signals via repression of peroxisome proliferator-activated receptor gamma."
    Park S.H., Choi H.J., Yang H., Do K.H., Kim J., Lee D.W., Moon Y.
    J. Biol. Chem. 285:35330-35339(2010) [PubMed] [Europe PMC] [Abstract]
    Cited for: FUNCTION.
  26. "Additional sex comb-like (ASXL) proteins 1 and 2 play opposite roles in adipogenesis via reciprocal regulation of peroxisome proliferator-activated receptor {gamma}."
    Park U.H., Yoon S.K., Park T., Kim E.J., Um S.J.
    J. Biol. Chem. 286:1354-1363(2011) [PubMed] [Europe PMC] [Abstract]
    Cited for: INTERACTION WITH ASXL1 AND ASXL2.
  27. "Familial focal segmental glomerulosclerosis (FSGS)-linked alpha-actinin 4 (ACTN4) protein mutants lose ability to activate transcription by nuclear hormone receptors."
    Khurana S., Chakraborty S., Lam M., Liu Y., Su Y.T., Zhao X., Saleem M.A., Mathieson P.W., Bruggeman L.A., Kao H.Y.
    J. Biol. Chem. 287:12027-12035(2012) [PubMed] [Europe PMC] [Abstract]
    Cited for: INTERACTION WITH ACTN4.
  28. Cited for: FUNCTION, INTERACTION WITH HELZ2 AND THRAP3, SUBCELLULAR LOCATION.
  29. "Crystal structure of the ligand binding domain of the human nuclear receptor PPARgamma."
    Uppenberg J., Svensson C., Jaki M., Bertilsson G., Jendeberg L., Berkenstam A.
    J. Biol. Chem. 273:31108-31112(1998) [PubMed] [Europe PMC] [Abstract]
    Cited for: X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 232-505.
  30. "Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma."
    Nolte R.T., Wisely G.B., Westin S., Cobb J.E., Lambert M.H., Kurokawa R., Rosenfeld M.G., Willson T.M., Glass C.K., Milburn M.V.
    Nature 395:137-143(1998) [PubMed] [Europe PMC] [Abstract]
    Cited for: X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 235-504 IN COMPLEXES WITH THE SYNTHETIC AGONIST ROSIGLITAZONE AND NCOA1, SUBUNIT.
  31. "Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors."
    Gampe R.T. Jr., Montana V.G., Lambert M.H., Miller A.B., Bledsoe R.K., Milburn M.V., Kliewer S.A., Willson T.M., Xu H.E.
    Mol. Cell 5:545-555(2000) [PubMed] [Europe PMC] [Abstract]
    Cited for: X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) IN COMPLEXES WITH RXRA AND SYNTHETIC AGONISTS.
  32. "Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors."
    Xu H.E., Lambert M.H., Montana V.G., Plunket K.D., Moore L.B., Collins J.L., Oplinger J.A., Kliewer S.A., Gampe R.T. Jr., McKee D.D., Moore J.T., Willson T.M.
    Proc. Natl. Acad. Sci. U.S.A. 98:13919-13924(2001) [PubMed] [Europe PMC] [Abstract]
    Cited for: X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 234-505 IN COMPLEXES WITH SYNTHETIC AGONIST AND NCOA1.
  33. "Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family."
    Cronet P., Petersen J.F.W., Folmer R., Blomberg N., Sjoeblom K., Karlsson U., Lindstedt E.-L., Bamberg K.
    Structure 9:699-706(2001) [PubMed] [Europe PMC] [Abstract]
    Cited for: X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) OF 225-505 IN COMPLEX WITH SYNTHETIC AGONIST.
  34. "Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar."
    Ebdrup S., Pettersson I., Rasmussen H.B., Deussen H.-J., Frost Jensen A., Mortensen S.B., Fleckner J., Pridal L., Nygaard L., Sauerberg P.
    J. Med. Chem. 46:1306-1317(2003) [PubMed] [Europe PMC] [Abstract]
    Cited for: X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 230-505 IN COMPLEX WITH SYNTHETIC AGONIST.
  35. "A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects."
    Oestberg T., Svensson S., Selen G., Uppenberg J., Thor M., Sundbom M., Sydow-Baeckman M., Gustavsson A.-L., Jendeberg L.
    J. Biol. Chem. 279:41124-41130(2004) [PubMed] [Europe PMC] [Abstract]
    Cited for: X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 232-505 IN COMPLEX WITH NCOA2 AND SYNTHETIC AGONIST.
  36. Cited for: X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 235-505 IN COMPLEX WITH RXRA; NCOA1 AND SYNTHETIC AGONIST.
  37. "Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity."
    Shi G.Q., Dropinski J.F., McKeever B.M., Xu S., Becker J.W., Berger J.P., MacNaul K.L., Elbrecht A., Zhou G., Doebber T.W., Wang P., Chao Y.-S., Forrest M., Heck J.V., Moller D.E., Jones A.B.
    J. Med. Chem. 48:4457-4468(2005) [PubMed] [Europe PMC] [Abstract]
    Cited for: X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 231-505 IN COMPLEX WITH SYNTHETIC AGONIST.
  38. "Structural and biochemical basis for selective repression of the orphan nuclear receptor liver receptor homolog 1 by small heterodimer partner."
    Li Y., Choi M., Suino K., Kovach A., Daugherty J., Kliewer S.A., Xu H.E.
    Proc. Natl. Acad. Sci. U.S.A. 102:9505-9510(2005) [PubMed] [Europe PMC] [Abstract]
    Cited for: X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 234-505 IN COMPLEX WITH SYNTHETIC AGONIST AND NR0B2.
  39. "Design and synthesis of novel N-sulfonyl-2-indole carboxamides as potent PPAR-gamma binding agents with potential application to the treatment of osteoporosis."
    Hopkins C.R., O'neil S.V., Laufersweiler M.C., Wang Y., Pokross M., Mekel M., Evdokimov A., Walter R., Kontoyianni M., Petrey M.E., Sabatakos G., Roesgen J.T., Richardson E., Demuth T.P. Jr.
    Bioorg. Med. Chem. Lett. 16:5659-5663(2006) [PubMed] [Europe PMC] [Abstract]
    Cited for: X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 234-505 IN COMPLEX WITH SYNTHETIC AGONIST AND NCOA1.
  40. "Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies."
    Mahindroo N., Wang C.-C., Liao C.-C., Huang C.-F., Lu I.-L., Lien T.-W., Peng Y.-H., Huang W.-J., Lin Y.-T., Hsu M.-C., Lin C.-H., Tsai C.-H., Hsu J.-T., Chen X., Lyu P.-C., Chao Y.-S., Wu S.-Y., Hsieh H.-P.
    J. Med. Chem. 49:1212-1216(2006) [PubMed] [Europe PMC] [Abstract]
    Cited for: X-RAY CRYSTALLOGRAPHY (2.07 ANGSTROMS) OF 235-505 IN COMPLEX WITH SYNTHETIC AGONIST.
  41. "Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities."
    Lu I.-L., Huang C.-F., Peng Y.-H., Lin Y.-T., Hsieh H.-P., Chen C.-T., Lien T.-W., Lee H.-J., Mahindroo N., Prakash E., Yueh A., Chen H.-Y., Goparaju C.M.V., Chen X., Liao C.-C., Chao Y.-S., Hsu J.-T., Wu S.-Y.
    J. Med. Chem. 49:2703-2712(2006) [PubMed] [Europe PMC] [Abstract]
    Cited for: X-RAY CRYSTALLOGRAPHY (2.54 ANGSTROMS) OF 235-505 IN COMPLEX WITH SYNTHETIC AGONIST.
  42. "Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR-gamma) gene in diabetic Caucasians: identification of a pro12ala PPAR-gamma-2 missense mutation."
    Yen C.-J., Beamer B.A., Negri C., Silver K., Brown K.A., Yarnall D.P., Burns D.K., Roth J., Shuldiner A.R.
    Biochem. Biophys. Res. Commun. 241:270-274(1997) [PubMed] [Europe PMC] [Abstract]
    Cited for: VARIANT ALA-12.
  43. "Obesity associated with a mutation in a genetic regulator of adipocyte differentiation."
    Ristow M., Muller-Wieland D., Pfeiffer A., Krone W., Kahn C.R.
    N. Engl. J. Med. 339:953-959(1998) [PubMed] [Europe PMC] [Abstract]
    Cited for: VARIANT OBESITY GLN-113.
  44. "A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity."
    Deeb S.S., Fajas L., Nemoto M., Pihlajamaeki J., Mykkaenen L., Kuusisto J., Laakso M., Fujimoto W., Auwerx J.
    Nat. Genet. 20:284-287(1998) [PubMed] [Europe PMC] [Abstract]
    Cited for: ASSOCIATION OF VARIANT ALA-12 WITH BMI.
  45. "Missense variants in the human peroxisome proliferator-activated receptor-gamma2 gene in lean and obese subjects."
    Hamann A., Munzberg H., Buttron P., Busing B., Hinney A., Mayer H., Siegfried W., Hebebrand J., Greten H.
    Eur. J. Endocrinol. 141:90-92(1999) [PubMed] [Europe PMC] [Abstract]
    Cited for: VARIANT ALA-12.
  46. "Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women."
    Valve R., Sivenius K., Miettinen R., Pihlajamaeki J., Rissanen A., Deeb S.S., Auwerx J., Uusitupa M., Laakso M.
    J. Clin. Endocrinol. Metab. 84:3708-3712(1999) [PubMed] [Europe PMC] [Abstract]
    Cited for: ASSOCIATION OF VARIANT ALA-12 WITH BMI.
  47. "Loss-of-function mutations in PPAR-gamma associated with human colon cancer."
    Sarraf P., Mueller E., Smith W.M., Wright H.M., Kum J.B., Aaltonen L.A., de la Chapelle A., Spiegelman B.M., Eng C.
    Mol. Cell 3:799-804(1999) [PubMed] [Europe PMC] [Abstract]
    Cited for: VARIANTS COLON CANCER PRO-314 AND HIS-316, VARIANT ALA-12.
  48. "Dominant negative mutations in human PPAR-gamma associated with severe insulin resistance, diabetes mellitus and hypertension."
    Barroso I., Gurnell M., Crowley V.E.F., Agostini M., Schwabel J.W., Soos M.A., Masien G.L., Williams T.D.M., Lewis H., Schafer A.J., Chatterjee V.K.K., O'Rahilly S.
    Nature 402:880-883(1999) [PubMed] [Europe PMC] [Abstract]
    Cited for: VARIANTS DIABETES MET-318 AND LEU-495.
  49. "PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy."
    Hegele R.A., Cao H., Frankowski C., Mathews S.T., Leff T.
    Diabetes 51:3586-3590(2002) [PubMed] [Europe PMC] [Abstract]
    Cited for: VARIANT FPLD3 LEU-388.
  50. "A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy."
    Agarwal A.K., Garg A.
    J. Clin. Endocrinol. Metab. 87:408-411(2002) [PubMed] [Europe PMC] [Abstract]
    Cited for: VARIANT FPLD3 CYS-425.
  51. "Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis."
    Masud S., Ye S.
    J. Med. Genet. 40:773-780(2003) [PubMed] [Europe PMC] [Abstract]
    Cited for: ASSOCIATION OF VARIANT ALA-12 WITH BMI.
  52. "Ala12Ala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosis."
    Temelkova-Kurktschiev T., Hanefeld M., Chinetti G., Zawadzki C., Haulon S., Kubaszek A., Koehler C., Leonhardt W., Staels B., Laakso M.
    J. Clin. Endocrinol. Metab. 89:4238-4242(2004) [PubMed] [Europe PMC] [Abstract]
    Cited for: ASSOCIATION OF VARIANT ALA-12 WITH CIMT.
  53. "Effects of peroxisome proliferator-activated receptor-gamma 2 Pro12Ala polymorphism on body fat distribution in female Korean subjects."
    Kim K.S., Choi S.M., Shin S.U., Yang H.S., Yoon Y.
    Metabolism 53:1538-1543(2004) [PubMed] [Europe PMC] [Abstract]
    Cited for: VARIANT ALA-12.

Entry informationi

Entry nameiPPARG_HUMAN
AccessioniPrimary (citable) accession number: P37231
Secondary accession number(s): A8K3G6
, B5BUA1, O00684, O00710, O14515, Q0QJH8, Q15178, Q15179, Q15180, Q15832, Q86U60, Q96J12
Entry historyi
Integrated into UniProtKB/Swiss-Prot: October 1, 1994
Last sequence update: April 27, 2001
Last modified: July 22, 2015
This is version 211 of the entry and version 3 of the sequence. [Complete history]
Entry statusiReviewed (UniProtKB/Swiss-Prot)
Annotation programChordata Protein Annotation Program
DisclaimerAny medical or genetic information present in this entry is provided for research, educational and informational purposes only. It is not in any way intended to be used as a substitute for professional medical advice, diagnosis, treatment or care.

Miscellaneousi

Keywords - Technical termi

3D-structure, Complete proteome, Reference proteome

Documents

  1. Human chromosome 3
    Human chromosome 3: entries, gene names and cross-references to MIM
  2. Human entries with polymorphisms or disease mutations
    List of human entries with polymorphisms or disease mutations
  3. Human polymorphisms and disease mutations
    Index of human polymorphisms and disease mutations
  4. MIM cross-references
    Online Mendelian Inheritance in Man (MIM) cross-references in UniProtKB/Swiss-Prot
  5. PDB cross-references
    Index of Protein Data Bank (PDB) cross-references
  6. SIMILARITY comments
    Index of protein domains and families

External Data

Dasty 3

Similar proteinsi

Links to similar proteins from the UniProt Reference Clusters (UniRef) at 100%, 90% and 50% sequence identity:
100%UniRef100 combines identical sequences and sub-fragments with 11 or more residues from any organism into Uniref entry.
90%UniRef90 is built by clustering UniRef100 sequences that have at least 90% sequence identity to, and 80% overlap with, the longest sequence (a.k.a seed sequence).
50%UniRef50 is built by clustering UniRef90 seed sequences that have at least 50% sequence identity to, and 80% overlap with, the longest sequence in the cluster.